Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Amgn | Rare Historical Photos

How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.

Barchart

Is Merck Stock Outperforming the Nasdaq?

Merck has surged past the broader Nasdaq Composite over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Barchart

Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Amgen Earnings Preview: What to Expect

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Barchart

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

MarketBeat

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Barchart

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

S&P 500 Hits New High on Apple Earnings: Stock Market Today

Apple rounded out a big week of mega-cap earnings on a high note, sending two of the three main equity indexes to new highs on Friday.

Kiplinger

What Are Wall Street Analysts' Target Price for Amgen Stock?

Amgen has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

What to Expect From Amgen's Next Quarterly Earnings Report

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

Barchart

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

How Is Merck & Co.'s Stock Performance Compared to Other Healthcare Stocks?

Despite Merck & Co.’s strong performance relative to its peers over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Dow Leads in Mixed Session on Amgen Earnings: Stock Market Today

The rest of Wall Street struggled as Advanced Micro Devices earnings caused a chip-stock sell-off.

Barchart

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Kiplinger

Dow Hits New High Then Falls 466 Points: Stock Market Today

The Nasdaq Composite, with a little help from tech's friends, rises to within 300 points of its own new all-time high.

Barchart

What to Expect From Amgen's Q4 2025 Earnings Report

Amgen will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit profit dip.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

MarketBeat

Amgen Stock: New All-Time Highs Ahead After Earnings Beat

Amgen stock jumps after a strong beat-and-raise quarter, pushing shares near split-adjusted all-time highs and signaling more upside ahead

Kiplinger

Stocks Rally as Investors Buy the Dip: Stock Market Today

Most sectors are "go" only a day after talk of bubbles, extended valuations and narrow breadth undermined any kind of exuberance.

Barchart

Amgen Stock: Analyst Estimates & Ratings

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

Barchart

The Saturday Spread: Using Data Science to Find Call Spreads Priced in Your Favor

It’s already difficult enough when you step into the world of options. Here’s how to even up the odds against the big dogs.

Barchart

Here's What to Expect From Amgen’s Next Earnings Report

Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.

Benzinga

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.